Home > Boards > US Listed > Medical - Healthcare > Arvinas, Inc. (ARVN)

ARVN up 138% > "Based on data to

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
crudeoil24 Member Profile
Member Level 
Followed By 676
Posts 45,395
Boards Moderated 12
Alias Born 12/12/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2021 6:01:01 PM
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021 GlobeNewswire Inc. - 4/5/2021 4:30:00 PM
'Data-rich 2H21' could send Arvinas shares 140% higher, Cantor says Seeking Alpha - 3/30/2021 10:22:25 AM
Arvinas to Participate in Upcoming Virtual Investor Conferences GlobeNewswire Inc. - 3/10/2021 4:30:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/1/2021 5:02:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/1/2021 4:05:14 PM
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 3/1/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/23/2021 6:10:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/18/2021 5:26:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/18/2021 5:17:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/18/2021 5:10:00 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 2/18/2021 5:01:53 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 6:44:54 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2021 4:48:37 PM
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day GlobeNewswire Inc. - 2/8/2021 4:30:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/8/2021 10:16:53 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/28/2021 4:16:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 4:32:08 PM
Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire Inc. - 12/28/2020 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:00:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/18/2020 6:30:41 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/16/2020 4:02:36 PM
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock GlobeNewswire Inc. - 12/15/2020 8:34:53 PM
Arvinas’ Cancer Drug Has Blockbuster Potential, Says Analyst TipRanks - 12/15/2020 7:48:04 PM
crudeoil24 Member Level  Monday, 12/14/20 09:19:37 AM
Re: None
Post # of 25 
ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences